ResearchMoz

Non Small Cell Lung Cancer Market Research Reports & Industry Analysis

Non Small Cell Lung Cancer Market Research Reports & Industry Analysis Non Small Cell Lung Cancer

Browse reports in Non Small Cell Lung Cancer

Displaying 1 to 19 (of 19 records)
Pages: « Last  1   
Gemzar (Non Small Cell Lung Cancer) Analysis and Forecasts to 2015
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Gemzar (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2015 provides Gemzar sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002- 2015). The report also includes...
$2000
Tarceva (Non Small Cell Lung Cancer) Analysis and Forecasts to 2015
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Tarceva (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides Tarceva sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes...
$2000
Vargatef (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Vargatef (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides Vargatef sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes...
$2000
Cisplatin (Non Small Cell Lung Cancer) Analysis and forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Cisplatin (Non Small Cell Lung Cancer) - Analysis and Estimates from 2002 to 2020 provides cisplatin sales estimates for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report...
$2000
Abraxane (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Abraxane (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides abraxane sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also...
$2000
ARQ 197 (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, ARQ 197 (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides ARQ 197 sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes...
$2000
Opaxio (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Opaxio (Non Small Cell Lung Cancer) - Analysis and Forecasts to 2020 provides Opaxio sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information...
$2000
Etoposide (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Etoposide (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Etoposide sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also...
$2000
Talactoferrin Alfa (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Talactoferrin Alfa (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Talactoferrin Alfa sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The...
$2000
Alimta (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Alimta (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Alimta sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes...
$2000
Stimuvax (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Stimuvax (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Stimuvax sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also...
$2000
Taxol (Non Small Cell Lung Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Taxol (Non Small Cell Lung Cancer)- Analysis and Forecasts to 2020 provides Taxol sales forecasts for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes...
$2000
Afatinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Afatinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Afatinib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes...
$2000
Taxotere (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Taxotere (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Taxotere's sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
Avastin (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Avastin (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Avastin sales Forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes...
$2000
Crizotinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Crizotinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Crizotinib sales forecasts for US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on...
$2000
Iressa (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary                                                                                      GlobalDatas pharmaceuticals report, Iressa (Non Small Cell Lung Cancer)-Analysis and...
$2000
Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Erbitux (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Erbitux sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes...
$2000
Navelbine (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Navelbine (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Comtan sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
 
Displaying 1 to 19 (of 19 records)
Pages: « Last  1